BofA analyst Jason Gerberry raised the firm’s price target on Arcellx (ACLX) to $77 from $65 and keeps a Buy rating on the shares. Citing Gilead’s (GILD) opt-in for Arcellx’s follow-on CAR-T program, ARC-SparX, and the recent positive CHMP opinion on competitor CAR-T Carvykti Cartitude-4, the firm now projects 5%-20% higher total company nominal revenue in 2026-30, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACLX: